Búsqueda Imágenes Maps Play YouTube Noticias Gmail Drive Más »
Búsqueda avanzada de patentes | Historial web | Iniciar sesión

Patentes

Número de publicaciónUS5690675 A
Tipo de publicaciónConcesión
Número de solicitud08/481,712
Fecha de publicación25 Nov 1997
Fecha de presentación7 Jun 1995
Fecha de prioridad13 Feb 1991
También publicado comoEP0901345A1, EP0901345A4, WO1996007356A1
Número de publicación08481712, 481712, US 5690675 A, US 5690675A, US-A-5690675, US5690675 A, US5690675A
InventoresCary J. Reich, Philip M. Sawyer, Philip N. Sawyer
Cesionario originalFusion Medical Technologies, Inc.
Enlaces externos: USPTO, Cesión de USPTO, Espacenet
Methods for sealing of staples and other fasteners in tissue
US 5690675 A
Resumen
Wounds in lung tissue are closed in a two step method consisting essentially of applying fasteners to a region adjacent to the wound, wherein the fasteners may cause penetrations. The fasteners are present in a preformed layer of collagen, fibrin, fibrinogen, elastin, albumin, or a combination thereof, and energy is applied to the region to fuse the material to the tissue and seal perforations in the tissue.
Imágenes(4)
Previous page
Next page
Reclamaciones
What is claimed is:
1. A method for closing a wound in tissue, said method consisting essentially of the following two steps performed sequentially:
applying fasteners selected from the group consisting of staples, clips, pins, hooks, and suture to a region adjacent to the wound to close the wound, wherein the fasteners cause penetrations in the tissue and the fasteners are present in a preformed layer of a material selected from the group consisting of collagen, fibrin, fibrinogen, elastin, albumin, and combinations, thereof, which fuses to the tissue upon the application of energy; and
applying energy selected from the heat, radiofrequency, laser, ultrasonic, and electrical energy to the region to fuse the material to the tissue and seal perforations in the tissue.
2. A method as in claim 1, wherein the layer comprises a solid or mesh layer.
3. A method as in claim 1, wherein the performed sheet has peripheral dimensions corresponding to the wound region.
4. A method as in claim 1, wherein the applied energy is selected from the group consisting of radio frequency energy, heat energy, laser energy, and ultrasonic energy.
5. A method as in claim 4 wherein the energy applying step comprises directing energy from a radio frequency inert gas coagulator applicator against the wound region.
6. A method as in claim 1, wherein the material comprises gelatin and the energy is applied at a level from 1 W/cm.sup.2 to 100 W/cm.sup.2 to fuse to the tissue without substantial loss of mechanical strength.
7. A method as in claim 1, wherein the fasteners are staples and applying the fasteners comprises simultaneously placing multiple staple lines with a stapler.
8. A method as in claim 1, wherein the material is a reinforced solid, wherein the reinforcement is composed of a non-bioabsorbable material.
9. A method for sealing a resection line in lung tissue, said method consisting essentially of the following two steps performed sequentially:
applying along the resection line fasteners selected from the group consisting of staples, clips, pins, hooks, and suture to close the lung tissue, wherein the fasteners are present in a preformed layer of a material selected from the group consisting of collagen, fibrin, fibrinogen, elastin, albumin, and combinations thereof, which fuses to the lung tissue upon the application of energy; and
applying energy selected from the heat, radiofrequency, laser, ultrasonic, and electrical enerqy to the region to fuse the material to the tissue and seal perforations in the tissue.
10. A method as in claim 9, wherein the fastener applying step is performed with an in-line stapler having a cutting blade disposed adjacent to a multiple staple line.
11. A method as in claim 9, wherein the applied energy is selected from the group consisting of radio frequency energy, heat energy, laser energy, and ultrasonic energy.
12. A method as in claim 1, wherein the energy applying step comprises directing energy from a radio frequency inert gas coagulator applicator against the material covering the wound region.
13. A method as in claim 9, wherein the material comprises gelatin and the energy is applied at a level from 1 W/ to 100 W/ to fuse to the tissue without substantial loss of mechanical strength.
14. A method as in claim 9, wherein the material is a reinforced solid, wherein the reinforcement is composed of a non-bioabsorbable material.
Descripción

The present invention is a continuatton-in-part of application Ser. No. 08/303,336, filed on Sep. 6, 1994, which was a continuation-in-part of application Ser. No. 08/007,691, filed on Jan. 22, 1993, now abandoned, which was a continuation-in-part of application Ser. No. 07/832,171; filed on Feb. 6, 1992, now abandoned, which was a continuation-in-part of application Ser. No. 07/654,860, filed on Feb. 13, 1991, now U.S. Pat. No. 5,156,613. The present application claims the benefit of the filing date of application Ser. No. 08/303,336 only. The full disclosure of application Ser. No. 08/303,336, is incorporated herein by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates generally to devices, articles, and methods for effecting and enhancing wound closure in tissue. More particularly, the present invention relates to the use of a fusible material together with fasteners for closing wounds, wherein energy is applied to the fusible material to seal the closure.

Chronic obstructive pulmonary diseases, such as emphysema and small airway diseases, affect from five to ten million people in the United States alone. In about ten percent of such cases, chronic alveolar inflammation is so severe that large portions of the lung are destroyed, resulting in greatly reduced oxygen exchange and significant breathing difficulties. Such cases can result in partial or complete disability, and in the worst cases death.

One procedure for treating advanced chronic obstructive pulmonary disease, referred to as a bullectomy or lung tailoring, involves the surgical excision of diseased lung tissue and suturing to close the lung along the excision line. Surgical resection of lung tissue is also performed for volume reduction, blebectomies, segmentectomies, lobectomies, wedge resections, bronchial resections, pneumonectomies, and pneumoreductions. Unfortunately, lung tissue is extremely fragile (particularly when weakened by diseases such as emphysema) and does not hold sutures well. The needle holes resulting from suturing can result in lung perforations which leak large amounts of air. Such post-operative air leaks often require long hospital stays and result in a high morbidity rate for the procedures. For these reasons, bullectomies where the lung is closed by suturing are seldom performed at present.

The prognosis for bullectomy procedures has been significantly improved by the introduction of modern surgical stapling techniques. Multiple row linear staplers have been used to both cut and close diseased lung tissue in both wedge resection and lobectomy procedures. Further improvement in such staple bullectomy procedures has been reported with the use of bovine pericardial strips to buttress and reinforce the staple line used to close the lung along the resection edge.

Although a significant improvement over prior procedures, the use of pericardium-reinforced stapling techniques during lung resection procedures is still problematic. The staple holes in the pericardial strips can still present small lung perforations, particularly when the strip is under pressure. Even very small perforations can result in air leakage as high as 2-5 liters/min. Moreover, the pericardial strips are not uniformly secured to the underlying lung tissue, and the terminal and side edges of the strip can separate from and/or tear the adjoining tissue, further contributing to air leakage. In particular, since the pericardial strips are attached to the underlying tissue only by the staples, air can leak from the staple perforations or elsewhere outward past the edges of the strip, i.e., pericardial strips do not seal the tissue closure in any significant way. Additionally, the use of bovine pericardial strips does not appear to promote healing of the underlying lung tissue, and particularly does not appear to promote fibroblast ingrowth to seal lung perforations which may be present after the procedure. Finally, present procedures do not provide for sealing or patching diseased areas of the lung other than by excising the diseased tissue and sealing along the excision line with staples with or without a pericardium patch. It would thus be desirable to provide procedures where diseased lung tissue could be sealed to prevent air leakage without the need to excise tissue.

2. Description of the Background Art

The use of bovine pericardial strips to reinforce lung staple lines in performing bullectomies for treating emphysema is described in Cooper (1994) Ann. Thorac. Surg. 57:1038-1039. Bovine pericardial strips of the type utilized for staple line reinforcement are commercially available from Bio-Vascular, Inc., St. Paul, Minn., under the trade name Peri-Strips™. U S. Pat. No. 5,156,613, PCT Application WO 92/14513, and copending application Ser. No. 08/231,998, assigned to the assignee of the present invention, describe a method for joining or reconstructing tissue by applying energy to a tissue site in the presence of a collagen filler material. Copending application Ser. No. 08/370,552, describes the use of an inert gas beam energy source for fusing collagen and other materials to tissue for joining or reconstructing the tissue. U.S. Pat. No. 5,071,417, describes the application of laser energy to biological materials to seal anastomoses. U.S. Pat. No. 5,209,776, describes protein materials which may be activated with energy and bonded to tissue. PCT Application WO 93/01758 describes an argon beam coagulator for treating tissue.

SUMMARY OF THE INVENTION

The present invention provides improved methods and devices for closing wounds in tissue using fasteners, such as staples, pins, hooks, sutures, and the like. The fasteners are applied to tissue in a conventional manner to close the wound, and energy is applied thereafter to a material disposed in a region over an adjacent wound which (upon application of the energy) fuses to the tissue to enhance the wound closure and seal perforations which may be present in the region due to fastener placement or other causes.

The fusible material is a biologic or biocompatible synthetic substance which will bond to underlying tissue upon application of energy from a suitable source, as described in more detail hereinafter. Preferred is the use of biological materials, such as proteins and protein-containing mixtures, which will bond to tissue proteins (e.g. covalently, non-covalently, physically, and combinations thereof) upon application of suitable activating energy. Exemplary biological materials include collagen, gelatin, elastin, fibrinogen, fibrin, albumin, and composites and mixtures thereof.

The fusible material may be applied to the wound region as a solid phase or as a non-solid dispersible phase. By "solid phase," it is meant that the fusible material is formed as a sheet, layer, film, strip, patch, mesh, or the like, over the wound region. By "non-solid dispersible phase," it is meant that the fusible material is in the form of a liquid, gel, powder, or combinations thereof, which may be spread, sprayed, painted, or otherwise dispersed over the wound region. Regardless of its initial state, the fusible material will be in the form of a solid or gel layer after energy has been applied according to the method of the present invention. That is, solid sheets, layers, films, strips, patches, and the like, will remain as a solid (although the dimensions may alter slightly as the material is softened and fused to the underlying tissue) while meshes and non-solids will be converted into solid or gel layers.

The fusible material may be applied before, during, or after placement of the fasteners, and is preferably applied together with the fasteners as a backing or reinforcement layer, where the fusible material is initially held in place by the fasteners and subsequently fused to the underlying tissue upon the application of energy. Such procedures are particularly advantageous since they require only two steps, i.e., the simultaneous placement of fastener and fusible material followed by the application of energy to fuse the material to tissue and enhance the tissue closure by sealing any perforations which may have resulted from the prior placement of the fasteners (as described above).

Optionally, the solid phase forms of the fusible material, such as sheets, layers, films, strips, and patches, may be reinforced with non-fusible materials to increase their strength and enhance their use as backings during the initial placement of the fasteners, particularly staples. Usually, the non-fusible materials will also be non-bioabsorbable so that the reinforcement material can remain in place to support the staples or other fasteners indefinitely. Exemplary reinforcement materials include meshes or braids composed of polymeric materials.

The methods of the present invention can rely on the application of energy from a wide variety of sources, including radiofrequency (RF) energy, laser energy, ultraviolet energy, ultrasonic energy, and the like. Preferred is the use of RF energy which can be provided by conventional electrosurgical power supplies operating at frequencies in the range from 200 kHz to 1.2. MHz. Particularly preferred is the use of RF energy applicators which provide a uniform, dispersed energy flux over a defined area, such as inert gas beam RF energy sources, more particularly argon beam RF energy sources. Standard electrocautery devices could also find use.

In the exemplary embodiment, the methods and devices of the present invention are used to enhance sealing of lung tissue in lung resection procedures where lung tissue has been removed along an excision line. Typically, the lung tissue is excised and closed using a conventional multiple row, linear stapler. The fusible material is applied as a backing or reinforcement layer with the staples, preferably being placed on or over the stapler head and/or anvil prior to stapling. The solid layer of fusible material thus acts as a mechanical support for the staples as they are initially placed in the fragile lung tissue. In addition to such initial mechanical support, however, the present invention provides for subsequent sealing of the lung tissue along and around the staple line by application of energy to the wound region to initiate fusion of the material to the underlying lung tissue. Fusion of the material effects sealing of perforations in the wound region which may be due to the initial stapling or other causes. In particular, sealing of the fusible material to the underlying tissue over regions adjacent to all sides of the staple line will inhibit or prevent leakage past the edges of the solid layer of fusible material which is formed. Additionally, fusing of the backing layer will provide "stress relief" to permit realignment of the individual staples to reduce tearing and damage to the lung tissue as the lung expands and contracts during respiration.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic illustration of a lung having diseased tissue regions.

FIGS. 2A-2E illustrate a method according to the principles of the present invention where a strip of fusible material is placed along an excision line prior to stapling and excision using a conventional stapling apparatus.

FIG. 3 illustrates a conventional stapling apparatus having a sleeve of fusible material disposed over the head and anvil.

FIGS. 4A and 4B illustrate an alternative method according to the present invention for excising and sealing diseased lung tissue, where the diseased tissue is first excised and stapled and a non-solid fusible material then applied over the stapled region prior to applying energy.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Methods and devices according to the present invention may be used for closing wounds in virtually any body tissue, and are particularly useful for closing wounds in the tissue of fragile body organs, such as lungs, stomach, liver, spleen, intestines, colon, and the like. The wounds may result from accidental trauma, surgical intervention, or virtually any other cause, with the methods and devices being particularly useful for the closure of surgical resections made in the lungs (lung volume reductions, bullectomies, lobectomies, segmentectomies, bronchial resections, wedge resections, pneumonectomies, pneumoreductions, etc.), in the gastrointestinal tract, (gastrectomies, intestinal/colon resection), in the liver, and in the spleen. The present invention provides both secure mechanical closure of the wound and prevention or inhibition of fluid leakage, including both air leakage and liquid fluid leakage, such as blood and other bodily fluids. The present invention is particularly suitable for performing lung resections where the remaining portion of the lung is closed and sealed along the resection line.

The present invention relies on the use of conventional surgical fasteners for initial closing of the wound. Exemplary fasteners include suture, staples, clips, pins, hooks, and the like. The present invention is particularly useful with surgical stapling devices, such as multiple row, in-line staplers of the type available from U.S. Surgical Corp., Norwalk, Conn., and Ethicon, Inc., Somerville, N.J., including both disposable and reusable devices, such as those devices intended for use in laparoscopic procedures.

The present invention particularly relies on applying a fusible material to the region on the outer tissue surface surrounding the wound, where the fusible material may penetrate at least to some extent to the inner wound surfaces that are being joined by the procedure. The fasteners used in the primary closure of the wound penetrations will usually cause perforations in the tissue surrounding the wound as the mechanical closure is effected. The presence of the fasteners in the penetrations will often impart some stress to the tissue, where the stress in turn can result in enlargement of the penetration(s). This is a particular problem with staple closures of the lung, where lung inflation during respiration can place significant stress on the lung tissue, especially at the edges of the resection line, causing the staples to enlarge the penetrations and permit significant air loss, as described previously. Stress can also concentrate at the edge of conventional pericardial patches, which in turn can tear lung tissue and cause air leakage. The fusible materials of the present invention (which upon application of energy bond and seal to the underlying tissue) can act to seal such perforations and enlarged penetrations and thus enhance the mechanical integrity of the wound closure. Moreover, solid sheets of fusible materials may be used as a backing or reinforcement layer to help anchor staples and other fasteners during initial placement of the fasteners prior to fusing.

The fusible material may be any natural, modified natural, or synthetic substance which has the ability to be applied over the wound region in a solid or non-solid state, and thereafter to be fused to the underlying tissue surrounding the closed wound upon the application of energy from a suitable energy source. Thus, the fusible material will be able to create and/or maintain a solid, continuous film over (and sometimes penetrating into) the wound region to act both to mechanically enhance the wound closure and/or seal any perforations which may be present in the region. Such fusible materials should also be biocompatible (e.g., should be non-immunogenic and non-inflammatory), and usually (but not necessarily) will be bioabsorbable overtime (e.g., being partially or completely resorbed into the underlying tissue over a period from 1 day to 90 days. Suitable synthetic materials include organic polymer films which contain or have been modified to contain side groups which will bond (covalently or hydrostatically) or otherwise adhere to the underlying tissue. Exemplary synthetic materials suitable for use in the present invention include organic polymers such as poly(lactic acid), poly(glycolic acid), poly(hydroxybutyrate), poly(phosphazine), polyester, and the like.

Generally, the use of natural biological polymers, and in particular biological proteins, is preferred. Suitable proteins include collagen, fibrin, fibrinogen, elastin, albumin, combinations thereof, and the like, and mixtures and derivatives thereof. Particularly preferred is the use of collagen and modified collagens, such as gelatin (which is a protein-containing material obtained by hydrolysis of collagen in a well known manner), as described in parent application Ser. No. 08/303,336, filed on Sep. 9, 1994, the full disclosure of which has been previously incorporated herein by reference. The fusible material will usually be applied to the wound region as a solid layer, e.g., in the form of a film, sheet, patch, strip, mesh, or the like. Use of a mesh allows tissue to form a coagulum within the interstices of the mesh as energy is applied, as described in patent application Ser. No. 08/303,336, the disclosure of which has been incorporated herein by reference.

The solid phase forms of the fusible material may optionally be reinforced with filaments, braids, meshes, and other woven and non-woven reinforcement materials. Preferably, the reinforcement materials will be non-bioabsorbable so that they will remain even after the fusible material has been resorbed. Thus, the reinforcement materials will remain to provide support for the fasteners over extended periods of time. Preferred reinforcement materials will be in the form of polymeric braids or meshes, particularly composed of polypropylene (Marlex (Gore-Tex

The solid phase forms of the fusible material may be formed by a variety of methods as described in copending application Ser. No. 08/303,336, the full disclosure of which has previously been incorporated herein by reference. Reinforcement materials can be added by various known techniques, such as impregnation, dipping, casting, co-extrusion, and the like.

Alternatively, the fusible material may be applied to the wound region in a non-solid dispersible state, e.g., as a liquid, gel, sol, paste, spray, or combination thereof. In the preferred solid layer form, the fusible material will be cut or trimmed into a desired shape prior to application to the wound region. Application to the wound region may occur before, during, or after application of the primary fasteners. In a particularly preferred embodiment, as described below, the fusible material will be applied to the tissue as a backing layer for the staples which are used as primary fasteners. Non-solid dispersible fusible materials may be applied using syringes, brushes, sprayers, spatulas, or other methods suitable for spreading or dispersing a thin layer of material over the wound region. In all cases, after application of the fusion energy, the fusible material will be in the form of a continuous solid film or gel over the wound region. That is, fusible materials which are originally in a solid, layer form will remain as a solid film, although the film will become bound to the underlying tissue and may alter in shape to some degree. In the case of non-solid and other discontinuous phases, the fusible material will be converted into a solid or gelatinous phase upon the application of energy. In the case of a fusible material which is applied in the form of a mesh, the application of energy will usually form a coagulum of tissue within the interstices of the mesh, resulting in a solid or gelatinous, continuous film comprising both the fusible material and the tissue coagulum after the energy has been applied.

In addition to the substances described above, the fusible material of the present invention may further include dyes, pigments, and the like, which affect the energy absorption of the material in some desired manner. For example, particular dyes may be added to enhance absorption of energy from the selected energy source. Additionally, dyes and pigments may be added simply to improve visualization of the material during use and/or permit materials having different characteristics to be distinguished from each other. Other substances and additives may be included with the fusible material for other purposes, as generally described in Parent application Ser. No. 08/303,336, filed on Sep. 9, 1994, the full disclosure of which has previously been incorporated herein by reference.

Other substances suitable for use as a component in the fusible material include glycosaminoglycans, such as hyaluronic acid, dermatan sulfate, chondroitin sulfate, and heparin. Use of the glycosaminoglycans is desirable since such materials, which are anti-thrombotics, can reduce adhesion to adjacent tissues and organs after the final solid or gelatinous layer has been formed by the application of energy.

The solid, forms of the fusible material will typically be provided as sheets, strips, films, or patches having a thickness sufficient to provide mechanical integrity both before and after application to the wound region. For most of the materials described above, and in particular for the collagen and gelatin materials, a thickness in the range from about 0.01 mm (0.5 mils) to 0.75 mm (30 mils), with a preferred thickness from 0.04 mm (1 mil) to 0.1 mm (4 mils) is suitable. Fusible materials having thicknesses generally greater than this range are less suitable since they have poor energy absorption characteristics and display increasing stiffness. Energy absorption and conduction within patches in the upper region of this range, from 0.1 mm to 0.75 mm, can be improved by the formation of holes partially or fully through the thickness of the material (referred to as "interlock vias" in Parent application Ser. No. 08/303,336, the full disclosure of which has previously been incorporated herein by reference). The peripheral dimensions of the continuous, solid sheets of fusible material are not critical. The sheets will typically be cut or trimmed to have a desired peripheral shape prior to use in the methods in the present invention. In a particularly preferred example, as described in more detail below, the sheets of fusible material may be formed into tubes, sleeves, or strips, which can be aligned along or over the heads and/or anvils of stapling devices, so that the materials will act as backing or reinforcement layers as the staples are applied to close the wound.

The method of the present invention will utilize energy of a type and in an amount sufficient to fuse the fusible material to underlying tissue. Suitable energy sources include electrical energy, particularly RF energy sources, heat energy, laser energy, ultrasonic energy, and the like. Preferred are the use of RF energy sources, such as those available as electrosurgical power supplies from companies such as Valleylab, Boulder, Colo., and Birtcher Medical Systems, Irvine, Calif., employing conventional RF-applying probes. Particularly preferred are modified radio frequency energy sources which provide for a dispersed or distributed current flow from a hand-held probe to the tissue. One such radio frequency energy source referred to as an inert gas beam coagulator which relies on flow of an inert ionizable gas, such as argon, for conducting current from the probe to the tissue.

Energy from the energy source will typically be manually directed to the tissue using a probe connected to an external power supply. The treating physician will manually direct the probe to apply energy over the surface of the fusible material and will visually confirm that fusion has been achieved. The probe may use conventional electrosurgical power supplies having an energy output from 2 W to 100 W, preferably from 20 W to 40 W. The fusible material will typically be exposed to the energy for a total time from about 5 seconds to 120 seconds, usually from 30 seconds to 40 seconds, for material having an area from 1 cm.sup.2 to 10 cm.sup.2. The precise timing will depend on the physician's visual assessment that fusion of the material to the underlying tissue has been achieved.

Referring now to FIG. 1, a lung L includes diseased regions R1 and R2. The diseased regions comprise giant bullae which are collapsing the adjoining gas-exchanging lung tissue. The methods and devices of the present invention may be advantageously used to resect such diseased regions R1 and R2 from the lung L and to further provide secure, generally air-tight seals along the resection lines.

Referring now to FIGS. 2A-2E, diseased region R1 can be removed by applying a strip of fusible material 10 along the desired resection line, as illustrated in FIG. 2A. Preferably, a second strip will be provided on the opposite side of the lung, where the two strips are aligned prior to stapling, as shown in FIG. 2B. A conventional multiple row, in-line stapling device having an axial cutting blade disposed between a pair of double staple lines is shown in FIG. 2B. The stapler is applied over the opposed pair of fusible material strips 10, and the strips stapled together to form a sandwich along the desired section line, as shown in FIG. 2C. It will be appreciated that the tissue (as well as the fusible strips 10) have been cut along line 12 after the stapling operation. A second pair of fusible strips are then placed along the remaining length of the desired recision line, and the stapling and recision step repeated using the same stapler having a new stapling cartridge. After the resected tissue is removed, energy is applied over the fusible material strips 10 and adjacent tissue area, typically using an inert gas beam coagulator 14 as shown in FIG. 2D.

Similar patching, stapling, and resecting steps are taken to remove the second diseased region R2, as shown in FIG. 2E. The method of the present invention is particularly useful since it also allows surface defects in the lung L to be corrected using patches 16, as also shown in FIG. 2E. The patch 16 can be cut to a desired size and geometry and placed over the lung defect. After placement, the inert gas beam coagulator 14 can be used to fuse the patch 16 to the lung tissue. At the end of the procedure, the diseased regions R1 and R2 have been removed, with the resulting resection lines sealed. Additionally, any surface defects in the lung L have been patched without tissue resection. Thus, the lung has been surgically repaired with the likelihood of perforations leading to air leaks being greatly reduced.

In order to enhance the integrity of the seal provided by tissue strips 10, it will generally be desirable to overlap the ends of multiple strips which are used in-line. Additionally, the strips 10 should extend beyond the resection line by a distance of at least 3 mm, preferably at least about 10 mm. In this way, a continuous sealing layer may be formed over all regions of the tissue which are at the greatest risk of air leakage.

In a preferred aspect of the present invention, the strips of fusible material may be initially placed over the head and/or anvil of a stapling device SD, as shown in FIG. 3. Preferably, sleeves 20 of the fusible material are wrapped around each of the anvil A and stapling head H, and secured by a strip of tape 22. The sleeves may be wrapped around the anvil head immediately prior to use, or preferably may be pre-formed and made available in a sterile package, where the physician may remove the sleeves immediately prior to use and place them over the stapling head. The sleeves may be provided in long, continuous lengths which may be cut into shorter segments having a desired length intended to fit over commercially available staplers, e.g., 50 mm, 55 mm, 65 mm, etc. The stapler may then be used to perform the method illustrated in FIGS. 2A-2E, except that there is no need to manually place strips of 10 of the fusible material prior to stapling. After stapling using the stapling device SD as shown in FIG. 3, the stapling head and anvil are separated from the cut sleeves 20, and the sleeve material may be trimmed to a desired width and geometry prior to the application of energy.

Liquid, gel, and other non-solid forms of the fusible material may be applied in a variety of manners. For example, a syringe SY may be used to apply a liquid fusible material over a wound region which has previously been stapled, as shown in FIG. 4A. The material may be applied, and optionally spread using a spatula or the like, and the fusion energy then applied using any of the sources described above, such as the inert gas beam coagulator 14 described previously. After application of energy, the fusible material will be in the form of a thin, continuous film of the material to protect and seal the wound region.

The following examples are offered by way of illustration, not by way of limitation.

EXPERIMENTAL Materials and Methods

1. Filtered Collagen Patch Preparation

Fibrous bovine corium collagen (Kensey-Nash Semed F collagen, Kensey-Nash Corporation, Exton, Pa.) was dispersed in distilled water at 10% solids (w/v). Polyethylene glycol 400 MW (PEG, U.S.P. or pharmaceutical grade) was also added to 1% solids (w/v). The dispersion was heated at 70 C. for 50 minutes with occasional agitation. The dispersion was then filtered through a 100 micron mesh. The filtrate was analyzed for percent solids and was adjusted to 4% solids (including PEG) by addition of distilled water. During the filtration and dilution steps, the filtrate was maintained at temperatures >35 filtrate. The filtrate was poured into dishes to form gels. To achieve the desired final patch thickness, 13 ml was poured into polystyrene petri dishes (100 Ill.) and allowed to gel at room temperature (20 To achieve a patch which is uniform in thickness, the poured filtrate and dish was maintained level. The poured filtrate gelled within 30 minutes, and the gel was allowed to dry at ambient conditions. Patches were dried until the moisture content reached 10-14%(w/w). Moisture levels below 10% were undesirable, since patches could become brittle. Dried films were freed from dishes and cross-linked with UV light; 254 nm at 4.4 watts/cm.sup.2 for 20-40 minutes (Model UVC-515 Ultraviolet Multi-linker, Ultra-Lum, Inc., Carson, Calif.). Patches were sterilized by placing in heat-sealed polyester barrier pouches, or equivalent moisture barrier enclosures, and irradiating with electron beam at 2.5-3.0 megarads (Nutek Corporation, Palo Alto, Calif.). The final dried, cross-linked patch was 0.04-0.06 mm thick, contained 8-20% PEG (w/w), with the remainder being cross-linked annealed gelatin. The melting temperature of the fully hydrated patch (hydrated in 0.1%aq. NaCl) by differential scanning calorimetry (DSC, Thermal Analyst 2100). TA Instruments, New Castle, Del.) was 34 collagen, which has a fully helical structure, melts at 50

2. Granular Collagen Patch Preparation

Fibrous bovine collagen was dispersed in distilled water at 3.3-3.8%(w/v), with 0.3%(w/v) PEG 400 MW, and heated as in the filtered formulation. After 50 min at 70 homogenizer (Virtis Cyclone IQ.sup.2, fitted with 20 mm diameter rotor-stator with flow-through head, containing slotted orifices with approximately 1 mm gap, operated at 20,000 rpm; net fluid flow through the head :150 ml/min, controlled by a pump external to the homogenizer; two complete passes through the homogenizer). Microscopic inspection of the collagen after heating and homogenization showed that all fibrous clumps were broken up. The homogenized dispersion was then poured into dishes (total protein solids 3.3-3.8%, w/v), gelled, dried, cross-linked, and sterilized as in the filtered patch formulation. These patches were 0.07-0.10 mm thick, due to the size of the fibers which are dried into the film. They were more opaque than the filtered formulation. DSC melting temperatures were 35

3. Gelatin Patch Formulation

Pharmaceutical grade gelatin, from bovine or porcine source (300 Bloom, Dynagel, Inc., Calumet City, Ill., or Hormel Foods Corp., Austin, Minn.) was dissolved at 3.3 to 3.8% (w/v) in distilled water, along with 0.3% PEG 400 MW (w/v), by heating 3-5 minutes at 50 stirring. The dissolved gelatin was cast into gels, dried, cross-linked, and sterilized as in the filtered patch formulation. These patches were 0.04 to 0.06 mm thick and almost transparent; DSC melting temperatures were 33

4. RF Energy Source

Radio frequency current was supplied by a Birtcher 6400 Argon Beam Coagulator equipped with a triple control hand piece (3:1 probe). Energy was applied at 40 W with an Argon flow of 4 liters/min.

5. Procedure

A pig (60 kg) was anesthetized, intubated, and prepared for a thoracotomy. A right thoracotomy was made through the fourth interspace, and a substantial portion of both the upper and lower lobes of the lung was exposed.

A 55 mm Ethicon Proximate Linear Cutter (Ethicon, Inc., Sommerville, N.J.) stapler was used to staple several locations in the lung, including (1) the lingula of the upper lobe, (2) the apex of the lower lobe, (3) the inferior aspect of the lower lobe which provided a relatively long 10 cm stapling site, and (4) a wedged-out segment of the lung. The filtered collagen patch, the granular patch, and the gelatin patch were each used for reinforcing the staple line applied to the lung.

Sheets of the filtered collagen patch, the granular patch, and the gelatin patch were placed over the stapler head and anvil prior to use. In both cases, the patch material was wrapped around the stapler head or anvil and secured as a tubular sleeve thereover by adhesive steri strips. The staples and the reinforcement patches were then applied to the lung tissue simultaneously in a single stapling and resection operation. After stapling was complete, the reinforcement patches were cut from the stapler head and anvil, trimmed and welded to the underlying lung tissue using the RF argon beam coagulator.

Results

The filtered collagen patch material the granular patch material, and the gelatin patch material were used successfully in the staple line reinforcement procedures. Each of the patch materials readily formed a tube which was easily wrapped around the stapler head/anvil. It appears that each of the filtered collagen, granular collagen, and gelatin welding patch materials can be formed as a cylindrical tube without the need to utilize external tapes or other closing devices. When initially stapled in place, prior to application of the RF energy, each of the reinforcement materials provided a strong buttress without cracking.

After fusion to the underlying tissue, no leaks were observed in the region surrounding the staples and/or fused patch material. Welding of the collagen and gelatin materials was particularly useful in preventing leakage at the axial ends of the patches. These patches further acted to prevent bleeding.

Although the foregoing invention has been described in detail for purposes of clarity of understanding, it will be obvious that certain modifications may be practiced within the scope of the appended claims.

Citas de patentes
Patente citada Fecha de presentación Fecha de publicación Solicitante Título
US4854320 *16 Jun 19878 Ago 1989Laser Surgery Software, Inc.Laser healing method and apparatus
US5071417 *15 Jun 199010 Dic 1991Rare Earth Medical Lasers, Inc.Laser fusion of biological materials
US5156613 *13 Feb 199120 Oct 1992Interface Biomedical Laboratories Corp.Collagen welding rod material for use in tissue welding
US5209776 *27 Jul 199011 May 1993The Trustees Of Columbia University In The City Of New YorkTissue bonding and sealing composition and method of using the same
US5503638 *10 Feb 19942 Abr 1996Bio-Vascular, Inc.Soft tissue stapling buttress
WO1992014513A1 *12 Feb 199214 Ago 1992Interface Biomedical Laboratories Corp.Filler material for use in tissue welding
WO1993001758A1 *14 Jul 19924 Feb 1993Jerome CanadySurgical coagulation device
Otras citas
Referencia
1Joel D. Cooper, MD "Technique to Reduce Air Leaks After Resection of Emphysematous Lung," Ann Thorac Surg, 57:1038-1039. (1994).
2 *Joel D. Cooper, MD Technique to Reduce Air Leaks After Resection of Emphysematous Lung, Ann Thorac Surg, 57:1038 1039. (1994).
3 *Oz, M. C. et al. SPIE vol. 1200, pp.55 59 (1990).
4Oz, M. C. et al. SPIE vol. 1200, pp.55-59 (1990).
5 *Product Brochure, Peri Guard Processed Bovine Pericardium, Bio Vascular, six pages, 98501 Rev. A (1992).
6 *Product Brochure, Peri Strips for Staple Line Reinforcement, Bio Vascular, Inc., two pages, Rev. 97003A (1994).
7Product Brochure, Peri-Guard Bio-Vascular, six pages, 98501 Rev. A (1992).
8Product Brochure, Peri-Strips™ for Staple Line Reinforcement, Bio-Vascular, Inc., two pages, Rev. 97003A (1994).
Citada por
Patente citante Fecha de presentación Fecha de publicación Solicitante Título
US5931165 *6 Feb 19973 Ago 1999Fusion Medical Technologies, Inc.Films having improved characteristics and methods for their preparation and use
US6110212 *7 Feb 199729 Ago 2000Kenton W. GregoryElastin and elastin-based materials
US6162241 *5 Ago 199819 Dic 2000Focal, Inc.Hemostatic tissue sealants
US618349820 Sep 19996 Feb 2001Devore Dale P.Methods and products for sealing a fluid leak in a tissue
US621758515 Ago 199717 Abr 2001Converge Medical, Inc.Mechanical stent and graft delivery system
US62939558 Oct 199925 Sep 2001Converge Medical, Inc.Percutaneous bypass graft and securing system
US63100369 Ene 199930 Oct 2001Last Chance Tissue Adhesives CorporationHigh strength, Bio-compatible tissue adhesive and methods for treating vigorously bleeding surfaces
US6338731 *17 Mar 199915 Ene 2002Ntero Surgical, Inc.Method and systems for reducing surgical complications
US63582692 Nov 199919 Mar 2002Ralph AyeMethod of treating peripheral bronchopleural fistulas
US636155910 Jun 199926 Mar 2002Converge Medical, Inc.Thermal securing anastomosis systems
US6372228 *30 Dic 199716 Abr 2002Kenton W. GregoryMethod of producing elastin, elastin-based biomaterials and tropoelastin materials
US6428561 *30 May 19976 Ago 2002Astra AktiebolagBiocompatible glue
US64948891 Sep 200017 Dic 2002Converge Medical, Inc.Additional sutureless anastomosis embodiments
US659930210 Jun 199929 Jul 2003Converge Medical, Inc.Aortic aneurysm treatment systems
US66269205 Jul 200130 Sep 2003Converge Medical, Inc.Distal anastomosis system
US664519820 Sep 200011 Nov 2003Ntero Surgical, Inc.Systems and methods for reducing post-surgical complications
US664890028 Nov 200118 Nov 2003Converge Medical, Inc.Anastomosis systems
US66489015 Dic 200018 Nov 2003Converge Medical, Inc.Anastomosis systems
US665254421 Nov 200125 Nov 2003Converge Medical, Inc.Percutaneous bypass graft and securing system
US6682520 *20 Abr 200127 Ene 2004Bistech, Inc.Tissue volume reduction
US6704210 *18 Dic 19979 Mar 2004Medtronic, Inc.Bioprothesis film strip for surgical stapler and method of attaching the same
US674010110 Jun 199925 May 2004Converge Medical, Inc.Sutureless anastomosis systems
US6773699 *9 Oct 200110 Ago 2004Tissue Adhesive Technologies, Inc.Light energized tissue adhesive conformal patch
US677557526 Feb 200210 Ago 2004D. Bommi BommannanSystem and method for reducing post-surgical complications
US67808409 Oct 200124 Ago 2004Tissue Adhesive Technologies, Inc.Method for making a light energized tissue adhesive
US684379521 Nov 200018 Ene 2005Converge Medical, Inc.Anastomotic connector for sutureless anastomosis systems
US685803521 Nov 200122 Feb 2005Converge Medical, Inc.Distal anastomosis system
US68754279 Oct 20015 Abr 2005Tissue Adhesive Technologies, Inc.Light energized tissue adhesive
US688724921 Nov 20003 May 2005Converge Medical Inc.Positioning systems for sutureless anastomosis systems
US69393649 Oct 20016 Sep 2005Tissue Adhesive Technologies, Inc.Composite tissue adhesive
US697202311 Abr 20026 Dic 2005Converge Medical, Inc.Distal anastomosis system
US708363112 Sep 20021 Ago 2006Converge Medical, Inc.Percutaneous bypass graft and securing system
US730042811 Dic 200427 Nov 2007Aeris Therapeutics, Inc.Tissue volume reduction
US737792815 Abr 200327 May 2008Cook Biotech IncorporatedApparatus and method for producing a reinforced surgical staple line
US74317309 May 20037 Oct 2008Tyco Healthcare Group LpSurgical stapling apparatus having a wound closure material applicator assembly
US765499823 Ago 20002 Feb 2010Aeris Therapeutics, Inc.Tissue volume reduction
US766564618 Jun 200723 Feb 2010Tyco Healthcare Group LpInterlocking buttress material retention system
US771731330 Sep 200518 May 2010Tyco Healthcare Group LpSurgical apparatus and structure for applying sprayable wound treatment material
US774462414 Oct 200529 Jun 2010Tyco Healthcare Group LpExtraluminal sealant applicator and method
US774462717 Jun 200329 Jun 2010Tyco Healthcare Group LpAnnular support structures
US778988928 Ene 20087 Sep 2010Cook Biotech IncorporatedApparatus and method for producing a reinforced surgical staple line
US779381328 Feb 200614 Sep 2010Tyco Healthcare Group LpHub for positioning annular structure on a surgical device
US77970566 Sep 200614 Sep 2010Nmt Medical, Inc.Removable intracardiac RF device
US782359212 Oct 20052 Nov 2010Tyco Healthcare Group LpAnnular adhesive structure
US7833234 *30 Sep 200516 Nov 2010Sofradim ProductionAppliance for storing, distributing and placing surgical fasteners
US784553322 Jun 20077 Dic 2010Tyco Healthcare Group LpDetachable buttress material retention systems for use with a surgical stapling device
US784553624 Mar 20067 Dic 2010Tyco Healthcare Group LpAnnular adhesive structure
US788695124 Nov 200815 Feb 2011Tyco Healthcare Group LpPouch used to deliver medication when ruptured
US790922414 Ene 201022 Mar 2011Tyco Healthcare Group LpInterlocking buttress material retention system
US792274314 Oct 200512 Abr 2011Tyco Healthcare Group LpStructure for applying sprayable wound treatment material
US792303128 Ene 200512 Abr 2011Ferrosan Medical Devices A/SHaemostatic sprays and compositions
US792343123 Dic 200212 Abr 2011Ferrosan Medical Devices A/SHaemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
US793830730 Sep 200510 May 2011Tyco Healthcare Group LpSupport structures and methods of using the same
US79505616 Abr 200931 May 2011Tyco Healthcare Group LpStructure for attachment of buttress material to anvils and cartridges of surgical staplers
US795116616 Oct 200731 May 2011Tyco Healthcare Group LpAnnular support structures
US795528811 Dic 20037 Jun 2011Ferrosan Medical Devices A/SGelatine-based materials as swabs
US796717931 Mar 200928 Jun 2011Tyco Healthcare Group LpCenter cinch and release of buttress material
US797235711 Dic 20075 Jul 2011Tyco Healthcare Group LpExtraluminal sealant applicator and method
US798802713 Ago 20092 Ago 2011Tyco Healthcare Group LpCrimp and release of suture holding buttress material
US798869027 Ene 20052 Ago 2011W.L. Gore & Associates, Inc.Welding systems useful for closure of cardiac openings
US801155031 Mar 20096 Sep 2011Tyco Healthcare Group LpSurgical stapling apparatus
US801155523 Dic 20086 Sep 2011Tyco Healthcare Group LpSurgical stapling apparatus
US80161775 Ene 201113 Sep 2011Tyco Healthcare Group LpStaple buttress retention system
US801617831 Mar 200913 Sep 2011Tyco Healthcare Group LpSurgical stapling apparatus
US801684914 Oct 200513 Sep 2011Tyco Healthcare Group LpApparatus for applying wound treatment material using tissue-penetrating needles
US80216847 Jul 200520 Sep 2011Ferrosan Medical Devices A/SHaemostatic composition comprising hyaluronic acid
US802888325 Oct 20074 Oct 2011Tyco Healthcare Group LpMethods of using shape memory alloys for buttress attachment
US803804525 May 200718 Oct 2011Tyco Healthcare Group LpStaple buttress retention system
US806233027 Jun 200722 Nov 2011Tyco Healthcare Group LpButtress and surgical stapling apparatus
US80661692 Mar 201029 Nov 2011Tyco Healthcare Group LpStructure containing wound treatment material
US808311918 Mar 201127 Dic 2011Tyco Healthcare Group LpInterlocking buttress material retention system
US809282019 May 200910 Ene 2012Baxter International Inc.Dry hemostatic compositions and methods for their preparation
US809645813 Ene 201117 Ene 2012Tyco Healthcare Group LpPouch used to deliver medication when ruptured
US814679122 Jul 20103 Abr 2012Tyco Healthcare Group LpAnnular adhesive structure
US815714911 Jul 201117 Abr 2012Tyco Healthcare Group LpCrimp and release of suture holding buttress material
US815715115 Oct 200917 Abr 2012Tyco Healthcare Group LpStaple line reinforcement for anvil and cartridge
US815783031 Mar 201017 Abr 2012Tyco Healthcare Group LpApparatus for applying wound treatment material using tissue-penetrating needles
US81678956 Abr 20111 May 2012Tyco Healthcare Group LpAnastomosis composite gasket
US820172023 Dic 201019 Jun 2012Tyco Healthcare Group LpPouch used to deliver medication when ruptured
US82104149 Ago 20113 Jul 2012Tyco Healthcare Group LpStaple buttress retention system
US82257994 Nov 201024 Jul 2012Tyco Healthcare Group LpSupport structures and methods of using the same
US822598131 Mar 201024 Jul 2012Tyco Healthcare Group LpSurgical apparatus and structure for applying sprayable wound treatment material
US82310433 Ago 201131 Jul 2012Tyco Healthcare Group LpSurgical stapling apparatus
US823527319 May 20117 Ago 2012Tyco Healthcare Group LpCenter cinch and release of buttress material
US823601522 Jul 20107 Ago 2012Tyco Healthcare Group LpSeal element for anastomosis
US82459018 Sep 201121 Ago 2012Tyco Healthcare Group LpMethods of using shape memory alloys for buttress attachment
US825665419 Sep 20114 Sep 2012Tyco Healthcare Group LpStaple buttress retention system
US82573917 Feb 20114 Sep 2012Tyco Healthcare Group LpAnnular support structures
US82768004 Nov 20102 Oct 2012Tyco Healthcare Group LpSupport structures and methods of using the same
US828197531 Mar 20109 Oct 2012Tyco Healthcare Group LpSurgical apparatus and structure for applying sprayable wound treatment material
US82833207 Abr 20119 Oct 2012Ferrosan Medical Devices A/SHaemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostasis
US828684916 Dic 200816 Oct 2012Tyco Healthcare Group LpHub for positioning annular structure on a surgical device
US83039811 Jul 20116 Nov 2012Baxter Healthcare S.A.Fragmented polymeric compositions and methods for their use
US830804216 May 201113 Nov 2012Tyco Healthcare Group LpStructure for attachment of buttress material to anvils and cartridges of surgical stapler
US83080456 Oct 201013 Nov 2012Tyco Healthcare Group LpAnnular adhesive structure
US830804630 Nov 201113 Nov 2012Tyco Healthcare Group LpInterlocking buttress material retention system
US83128856 Oct 201020 Nov 2012Tyco Healthcare Group LpAnnular adhesive structure
US831301419 Oct 201020 Nov 2012Covidien LpSupport structures and methods of using the same
US832258831 Oct 20114 Dic 2012Covidien LpStructure containing wound treatment material
US83481261 Dic 20118 Ene 2013Covidien LpCrimp and release of suture holding buttress material
US834813010 Dic 20108 Ene 2013Covidien LpSurgical apparatus including surgical buttress
US835393021 Oct 201015 Ene 2013Covidien LpStructure for applying sprayable wound treatment material
US835737824 May 201122 Ene 2013Baxter International Inc.Fragmented polymeric compositions and methods for their use
US836597229 Abr 20115 Feb 2013Covidien LpSurgical stapling apparatus
US83714921 Dic 200912 Feb 2013Covidien LpSurgical stapling apparatus
US837149322 Ago 201112 Feb 2013Covidien LpSurgical stapling apparatus
US837209428 Sep 200512 Feb 2013Covidien LpSeal element for anastomosis
US838314121 Jul 200826 Feb 2013Baxter International Inc.Dry hemostatic compositions and methods for their preparation
US838865222 Jun 20105 Mar 2013Covidien LpSurgical stapling apparatus having a wound closure material applicator assembly
US84084401 Sep 20112 Abr 2013Covidien LpSurgical stapling apparatus
US84138715 Mar 20089 Abr 2013Covidien LpSurgical stapling apparatus
US842474231 Mar 201123 Abr 2013Covidien LpSupport structures and methods of using the same
EP1791473A2 *16 Ago 20056 Jun 2007Tyco Healthcare Group LpStapling support structures
WO1998016165A1 *15 Oct 199723 Abr 1998Fusion Medical Technologies, Inc.Films having improved characteristics and methods for their preparation and use
WO1998036707A1 *6 Feb 199827 Ago 1998Kenton W. GregoryMethod of producing biomaterials
WO2003094746A1 *9 May 200320 Nov 2003Tyco Healthcare Group, LpSurgical stapling apparatus having a wound closure material applicator assembly
WO2006023578A216 Ago 20052 Mar 2006Joshua B. StopekStapling support structures
WO2011092694A227 Ene 20114 Ago 2011Omrix Biopharmaceuticals Ltd.Method for improved fibrin sealing
Clasificaciones
Clasificación de EE.UU.606/229, 606/228, 606/27, 606/230, 606/214, 128/898, 606/32, 606/213
Clasificación internacionalA61F2/00, A61L27/24, A61B18/00, A61L15/32, A61B17/00, A61B18/22, A61B17/11, A61B17/072
Clasificación cooperativaA61B17/00491, A61L15/32, A61F2310/00365, A61B18/22, A61B18/042, A61B2017/00504, A61L27/24, A61B17/07292, A61L15/325, A61B17/11
Clasificación europeaA61B18/04B, A61B18/22, A61L15/32, A61B17/00L, A61L27/24, A61L15/32A, A61B17/11